Lyra Therapeutics (LYRA) EBITDA Margin (2021 - 2025)

Lyra Therapeutics has reported EBITDA Margin for 5 years, with the latest figure at 101685.71% in Q4 2025.

• On a quarterly basis, EBITDA Margin fell 9622734.0% year-over-year to 101685.71% in Q4 2025; TTM through Dec 2025 was 7794.47%, a 151364.0% decrease from a year earlier, with the FY2025 full-year figure at 7794.47%, down 151364.0% from the prior year.
• EBITDA Margin was 101685.71% for Q4 2025 at Lyra Therapeutics, down from 24948.0% in the prior quarter.
• The five-year high for EBITDA Margin was 2548.08% in Q1 2022, with the low at 137772.73% in Q4 2022.
• Average EBITDA Margin over 5 years is 23017.71%, with a median of 4931.81% recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin tumbled 13274025 bps in 2022, then surged 12648711 bps in 2023.
• Over 5 years, EBITDA Margin stood at 5032.47% in 2021, then tumbled by 2638 bps to 137772.73% in 2022, then surged by 92 bps to 11285.62% in 2023, then surged by 52 bps to 5458.37% in 2024, then slumped by 1763 bps to 101685.71% in 2025.
• The last three EBITDA Margin figures came in at 101685.71% (Q4 2025), 24948.0% (Q3 2025), and 4822.95% (Q2 2025), per Business Quant data.